April 29, 2010. EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the management of hyperuricemia associated with tumor lysis syndrome. This phase 1 trial assessed the safety, pharmacokinetics and pharmacodynamics of single intravenous doses of pegsitacase in 20 subjects (study details available at ClinicalTrials.gov). Each cohort received a single pegsitacase dose of 0...
More...
More...